ATE523788T1 - ASSAY ZUR DIAGNOSE VON ALZHEIMER BASIEREND AUF DER BESTIMMUNG DES VERHÄLTNISSES VON SEKRETASE-Aß-SPALTPRODUKTEN - Google Patents

ASSAY ZUR DIAGNOSE VON ALZHEIMER BASIEREND AUF DER BESTIMMUNG DES VERHÄLTNISSES VON SEKRETASE-Aß-SPALTPRODUKTEN

Info

Publication number
ATE523788T1
ATE523788T1 AT06011829T AT06011829T ATE523788T1 AT E523788 T1 ATE523788 T1 AT E523788T1 AT 06011829 T AT06011829 T AT 06011829T AT 06011829 T AT06011829 T AT 06011829T AT E523788 T1 ATE523788 T1 AT E523788T1
Authority
AT
Austria
Prior art keywords
ratio
alzheimer
diagnosis
determination
secretase
Prior art date
Application number
AT06011829T
Other languages
English (en)
Inventor
Gerd Multhaup
Lisa Muenter
Original Assignee
Fu Berlin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fu Berlin filed Critical Fu Berlin
Application granted granted Critical
Publication of ATE523788T1 publication Critical patent/ATE523788T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
AT06011829T 2006-06-08 2006-06-08 ASSAY ZUR DIAGNOSE VON ALZHEIMER BASIEREND AUF DER BESTIMMUNG DES VERHÄLTNISSES VON SEKRETASE-Aß-SPALTPRODUKTEN ATE523788T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06011829A EP1865326B1 (de) 2006-06-08 2006-06-08 Assay zur Diagnose von Alzheimer basierend auf der Bestimmung des Verhältnisses von Sekretase-Aß-Spaltprodukten

Publications (1)

Publication Number Publication Date
ATE523788T1 true ATE523788T1 (de) 2011-09-15

Family

ID=36922150

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06011829T ATE523788T1 (de) 2006-06-08 2006-06-08 ASSAY ZUR DIAGNOSE VON ALZHEIMER BASIEREND AUF DER BESTIMMUNG DES VERHÄLTNISSES VON SEKRETASE-Aß-SPALTPRODUKTEN

Country Status (6)

Country Link
US (1) US20100221759A1 (de)
EP (2) EP1865326B1 (de)
CN (1) CN101460853A (de)
AT (1) ATE523788T1 (de)
ES (1) ES2373048T3 (de)
WO (1) WO2007140843A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9017963B2 (en) * 2002-01-31 2015-04-28 Woundchek Laboratories (Us), Inc. Method for detecting microorganisms
JP5445844B2 (ja) * 2006-11-17 2014-03-19 フリードリッヒ−アレクサンダー−ユニバースィタット アーランゲン−ニュールンベルグ 血管性認知症の鑑別診断のための生体外の方法
US20100285597A1 (en) * 2007-05-24 2010-11-11 University Of Rochester Detection of fragments of nectin-1 for the diagnosis of alzheimer's disease
EA025107B1 (ru) * 2008-07-31 2016-11-30 Пробиодруг Аг Способ диагностирования болезни альцгеймера, нейродегенерации при синдроме дауна или легкого когнитивного нарушения у субъекта (варианты) и набор для осуществления способа
WO2010034072A1 (en) * 2008-09-26 2010-04-01 The University Of Melbourne Alzheimer's disease biomarkers
DE102009054057A1 (de) * 2009-11-20 2011-05-26 Charité - Universitätsmedizin Berlin (Charité) Screening-Verfahren für Wirkstoffe für die Prophylaxe und Therapie neurodegenerativer Erkrankungen
EP2511296A1 (de) 2011-04-12 2012-10-17 Araclón Biotech, S. L. Antikörper, Kit und Verfahren zur Bestimmung von Amyloidpeptiden
US9678086B2 (en) 2012-09-10 2017-06-13 The Johns Hopkins University Diagnostic assay for Alzheimer's disease
ES2498465B1 (es) * 2013-02-20 2015-09-17 Universidad Miguel Hernández De Elche Método de diagnóstico y/o pronóstico de la enfermedad de alzheimer
ES2874704T3 (es) * 2013-11-20 2021-11-05 Univ Iowa Res Found Procedimiento para monitorizar la eficacia de un tratamiento de la enfermedad de Alzheimer con una isoforma de ApoE
ES2933952T3 (es) * 2014-05-22 2023-02-15 Shimadzu Corp Biomarcador indirecto para evaluar la acumulación de péptido beta amiloide intracerebral y método para el análisis del mismo
CN105002172B (zh) * 2015-07-31 2017-07-11 北京泱深生物信息技术有限公司 检测eapp基因表达的试剂在诊治阿尔茨海默病中的应用
WO2022115705A2 (en) 2020-11-30 2022-06-02 Enigma Biointelligence, Inc. Non-invasive assessment of alzheimer's disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998021589A1 (en) * 1996-11-15 1998-05-22 The Trustees Of The University Of Pennsylvania Screening for modulators of amyloid processing
ES2318902T3 (es) * 1998-09-24 2009-05-01 PHARMACIA & UPJOHN COMPANY LLC Secretasa en la enfermedad del alzheimer.
CA2412925A1 (en) * 2000-07-06 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw A novel app mutation associated with an unusual alzheimer's disease pathology
EP1421198A4 (de) * 2001-06-26 2006-08-30 New York State Office Of Menta Screeningmethoden mit hohem durchsatz auf zellbasis
US20050208050A1 (en) * 2001-11-09 2005-09-22 Gerd Multhaup Compounds for the diagnosis/prevention/treatment of alzheimer's disease
WO2003103593A2 (en) * 2002-06-05 2003-12-18 Buck Institute Secretases related to alzheimer's dementia
ATE410696T1 (de) * 2004-05-24 2008-10-15 Univ Muenchen L Maximilians Identizifierung von antiprionwirkstoffen mittels screening mit hohem durchsatz auf sift-basis

Also Published As

Publication number Publication date
WO2007140843A2 (en) 2007-12-13
EP1865326A1 (de) 2007-12-12
US20100221759A1 (en) 2010-09-02
ES2373048T3 (es) 2012-01-30
WO2007140843A3 (en) 2008-04-24
EP2032990A2 (de) 2009-03-11
CN101460853A (zh) 2009-06-17
EP1865326B1 (de) 2011-09-07

Similar Documents

Publication Publication Date Title
WO2007140843A3 (en) Assay for the diagnosis of alzheimer's disease based on the determination of the ratio of gamma-secretase abeta cleavage products
MA29282B1 (fr) Procede de diagnostic d'une steatose hepatique au moyen de marqueurs biochimiques
ATE533061T1 (de) Verfahren zur diagnose bakterieller infektionen
ATE386942T1 (de) Verfahren zur voraussage, zur diagnose und zur vergleichenden diagnose von alzheimer
ATE493649T1 (de) Verfahren zur diagnose von polyzystischer nierenkrankheit
WO2007001342A3 (en) Exhaled breath condensate collection and assay system and method
SG141418A1 (en) Method for the detection of gene transcripts in blood and uses thereof
EP1810026A4 (de) B7-h1 und verfahren zur diagnose, prognose und behandlung von krebs
WO2010041046A8 (en) Granin proteins as markers of heart disease
WO2007028161A3 (en) Methods and compositions for identifying biomarkers useful in diagnosis and/or treatment of biological states
WO2006090389A3 (en) Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof
ATE511651T1 (de) Transglutaminase 6 als diagnostischer indikator für autoimmunerkrankungen
ATE375517T1 (de) Diagnosestellung von akuten myokardialen, ischämischen erkrankungen durch kombination von markern
AR054479A1 (es) Metodo para diagnosticar l a enfermedad de alzheimer
DE60326153D1 (de) Verfahren zur diagnose von morbus alzheimer
WO2007132120A3 (fr) Procede et methodes de detection de la maladie d'alzheimer
WO2007059064A3 (en) Fgf2-related methods for diagnosing and treating depression
TW200502400A (en) Nucleic acid detection
EP2287340A3 (de) Verfahren zur Diagnose und Behandlung einer Geisteskrankheit
EP1572225A4 (de) Thrombospondinfragmente und deren verwendung bei klinischen krebs-tests und der erzeugung von antikörpern und sonstigen bindungsmitteln
ATE535620T1 (de) Entwicklung eines echtzeit-pcr-tests zum nachweis von pneumokokken-dna und diagnose einer pneumokokkenerkrankung
ATE495271T1 (de) Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin
FR2930036B1 (fr) Procede de diagnostic d'une hypertension arterielle pulmonaire.
EP2062984A3 (de) Primer und Sonden zum Nachweis genitaler HPV-Genotypen
FR2936060B1 (fr) Procede de diagnostic d'une sclerodermie systemique ou d'une hypertension arterielle pulmonaire.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties